Major Investements for
AI-Based Cancer Diagnostics

Strengthening Innovation in Digital Oncology

 These financing rounds highlight the growing impact of EKFZ spin-offs in the field of AI-based cancer diagnostics. By translating research into scalable clinical solutions, StratifAI and Cancilico are helping to make oncology care more precise and data-driven. We congratulate both teams on this important milestone and are proud to see their innovations receive strong international support.

 StratifAI raised €12.5 million to advance its AI biomarker platform Polaris™

 Berlin-based StratifAI secured €12.5 million in a financing round led by Picus Capital and Alven. The funding will accelerate the clinical validation and regulatory approval of Polaris™, StratifAI’s multimodal AI biomarker platform for precision oncology. Polaris™ combines routine histology with gene expression data to identify spatial tumor signals and link them directly to patient outcomes. This fully digital approach aims to accelerate biomarker discovery, increase its scalability, and reduce costs. The first product, Polaris™ Breast, is designed to assess the risk of breast cancer recurrence. With the new capital, StratifAI plans to expand clinical collaborations in Europe and the United States and generate evidence for broader clinical adoption. The company is also expanding its international team to support global growth.

This investment enables us to build a scalable regulatory framework for developing clinical grade AI diagnostics, expand our ecosystem with diverse, high quality clinical data, and deliver better tests to support treatment decision making. With the support of our investors, who bring deep expertise in rapid execution and global scaling, we are setting a new standard for faster, more accessible clinical decision-making tools. By prioritizing biological diversity in our data, we are developing solutions that are globally applicable and positioning StratifAI at the forefront of the market. – Omar El Nahhas | CEO & Co-Founder at StratifAI

Cancilico Raised €2.5 Million to Scale AI-Based Bone Marrow Diagnostics

 The Dresden-based company closed a €2.5 million seed round led by High-Tech Gründerfonds (HTGF), TGFS – Technologiegründerfonds Sachsen, GEDAD GmbH, and ROI Verwaltungsgesellschaft. The funding will support the development and regulatory advancement of MyeloAID, Cancilico’s AI-powered software that analyzes bone marrow samples for blood cancer diagnostics. The platform uses large, validated datasets from malignant and healthy samples to enable faster, more accurate classification of hematological diseases. Designed as a platform-independent solution, MyeloAID can be integrated into existing laboratory infrastructure without the need for new hardware. The technology is currently available for research use only and aims to become a routine clinical tool in the future.

Bone marrow analysis is one of the most complex and time-intensive disciplines in hematology. By training our AI on a diverse range of healthy and pathological datasets, we developed a tool that acts as a highly skilled ‘digital colleague’. This funding is a crucial step toward bringing this technology to the labs, where it will help to make faster, more accurate diagnoses for blood cancer patients. – Dr. Moritz Middeke | CMO and Co-Founder at Cancilico